Search results
Results from the WOW.Com Content Network
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood.With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). They are found in raw plants/herbs such as cinnamon and bacteria (containing the inhibitor acarbose ).
The term "biguanidine" often refers specifically to a class of drugs that function as oral antihyperglycemic drugs used for diabetes mellitus or prediabetes treatment. [4] Examples include: Metformin - widely used in treatment of diabetes mellitus type 2; Phenformin - withdrawn from the market in most countries due to toxic effects
Metformin (INN; trade names Glucophage, Diabex, Diaformin, Fortamet, Riomet, Glumetza and others) is an anti-diabetic drug from the biguanide class of oral antihyperglycemic agents. Other biguanides include the withdrawn agents phenformin and buformin. Metformin is the most popular anti-diabetic drug in the United States and one of the most ...
Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006. [1]
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. [31] Ertugliflozin was approved in the United States under the brand name Steglatro in December 2017. [32] Ipragliflozin, produced by the Japanese company Astellas Pharma Inc. under the brand name Suglat, approved in Japan January 2014. [33] [34]